Life Biosciences

Partial reprogramming (OSK via AAV) · NAION, glaucoma (optic neuropathy)

IND-enablingPartial Epigenetic Reprogramming

Mechanism

Partial reprogramming (OSK via AAV)

Intervention class

Gene therapy

Indication

NAION, glaucoma (optic neuropathy)

Stage

IND-enabling

Evidence

animal

Funding

~$240M VC

Backers

Various

Overview

Sinclair-affiliated. Delivers three Yamanaka factors (OSK) to restore vision in damaged optic nerves — non-human primate data showed restored sight. First credible reprogramming-to-clinic story with a hard, measurable endpoint.

Technology

Life Biosciences works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.

Read the Partial Epigenetic Reprogramming brief →

Related companies

Altos Labs

Partial epigenetic reprogramming

Retro Biosciences

Reprogramming, autophagy, plasma factors

NewLimit

Epigenetic reprogramming (factor discovery)

Rejuvenate Bio

Gene therapy (FGF21, sTGFβR2, klotho); reprogramming

Turn Biotechnologies

mRNA epigenetic reprogramming

Shift Bioscience

Reprogramming w/o dedifferentiation

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.